Advanced Micronic Devices Ltd.
BSE: 517552 | Sector: Health care |
NSE: N.A. | ISIN Code: INE903C01013 |
BSE 00:00 | 10 Dec | Advanced Micronic Devices Ltd |
NSE 05:30 | 01 Jan | Advanced Micronic Devices Ltd |
OPEN | 9.55 |
PREVIOUS CLOSE | 9.55 |
VOLUME | 5 |
52-Week high | 9.55 |
52-Week low | 0.00 |
P/E | |
Mkt Cap.(Rs cr) | 5 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
Advanced Micronic Devices Ltd. (ADVANCEDMICRON) - News Sector
-
Lupin slips 9%, hits 2-year low on disappointing March quarter results
9.39 am | 19 May 2022 | Business Standard
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
-
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit
9.35 pm | 18 May 2022 | Business Standard
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
-
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD
9.25 pm | 18 May 2022 | Business Standard
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
-
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra
9.22 pm | 18 May 2022 | Business Standard
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
-
Rejuvenating Cipla: After global expansion, acquisitions on cards
9.18 pm | 18 May 2022 | Business Standard
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
-
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts
3.16 pm | 18 May 2022 | Business Standard
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
-
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
9.52 am | 18 May 2022 | Business Standard
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
-
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%
1.47 am | 18 May 2022 | Business Standard
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
-
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations
12.42 pm | 17 May 2022 | Business Standard
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
-
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore
1.05 am | 17 May 2022 | Press Trust of India
Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
-
USFDA rush after 2-year lull: 20-30% new products may be open to inspection
3.01 am | 16 May 2022 | Business Standard
The last two years saw limited physical inspections due to travel restrictions during the pandemic
-
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol
12.04 am | 14 May 2022 | Business Standard
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
-
Cipla looks to invest more in mRNA tech; holds discussions with firms
2.03 am | 12 May 2022 | Business Standard
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
-
Cipla will use Covid-19 bulk drugs inventory when demand rises
11.46 pm | 11 May 2022 | Business Standard
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
-
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4
12.27 pm | 11 May 2022 | Business Standard
In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
-
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun
8.11 am | 11 May 2022 | Business Standard
Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
-
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact
2.26 am | 11 May 2022 | Business Standard
For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
-
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483
1.22 am | 11 May 2022 | Business Standard
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
-
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far
11.10 pm | 10 May 2022 | Business Standard
Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
-
Rainbow Children's Medicare lists at 7% discount to issue price
10.30 am | 10 May 2022 | Business Standard
The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.
Quick Links for Advanced Micronic Devices:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices